entertainment -WSS

entertainment

author：leisure time 2025-09-30 23:06:17 - browse：857

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Study: Hearing aids may slow cognitive decline in those at risk

focus

hotspot

WSS

Travel bans should be based on evidence, not politics or fear

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

‘The Bear’ and hospitality in hospitals

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Sage's campaign to raise awareness of postpartum depression hits a nerve

hotspot

entertainment

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA seeking to stop procedures at two unregulated stem cell clinics

In Memoriam: Notable people who died in 2023

Flagship, Pfizer team up in deal worth up to $7 billion

Medical records are filled with copy

Astronauts get first look at the spacecraft that will fly them around the moon

New air purifier tech could be key to improving indoor air quality

Robert Kennedy Jr.'s presidential campaign attracts GOP

Heart attack and stroke risk calculators need revising

Johnson & Johnson sues to stop Medicare negotiation

knowledge

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

More regulation could be coming for drug ads

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Discs beat pads, tampons for heavy menstrual flow, new study shows

CDC launches VaccineFinder tool to locate Covid

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

focus

hotspot

explore

hotspot